Despite major advances in prevention and treatment, febrile neutropenia (absolute
neutrophil count <0.5 × 10(9)/L) remains one of the most concerning complications of cancer chemotherapy,
especially in patients receiving myelosuppressive chemotherapy [
[1]
]. Outside the context of Oncology, few data are currently available for febrile neutropenia,
especially for febrile neutropenia related to non-chemotherapy drugs, called “idiosyncratic
agranulocytosis”.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Management of neutropenia in cancer patients.Clin Adv Hematol Oncol. 2012; 10: 825-826
- Management of febrile neutropaenia: ESMO clinical practice guidelines.Ann Oncol. 2016; 27: 111-118
- Clinical presentation and management of drug-induced agranulocytosis.Expert Rev Hematol. 2011; 4: 143-151
- Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature.Eur J Intern Med. 2002; 13: 324-328
- Prognostic factors of hematological recovery in nonchemotherapy drug-induced agranulocytosis.Haematologica. 2003; 88: 470-471
- Non-chemotherapy drug-induced agranulocytosis: a systematic review of case reports.Ann Intern Med. 2007; 146: 657-665
Article info
Publication history
Published online: August 17, 2017
Accepted:
August 15,
2017
Received:
August 11,
2017
Identification
Copyright
© 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
